These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35102484)

  • 1. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
    Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
    Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Japanese case of melanoma of unknown origin with a rare BRAF
    Kuriyama H; Kimura T; Mizuhashi S; Nishimura Y; Kanemaru H; Kajihara I; Makino K; Aoi J; Matsui H; Fukushima S
    Drug Discov Ther; 2022 Nov; 16(5):256-257. PubMed ID: 36273892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
    Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
    Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
    Carrabba NV; Siliezar PD; Laylani N; Lee AG
    Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
    Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
    Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
    Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
    J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
    [No Abstract]   [Full Text] [Related]  

  • 9. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 13. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
    Pedersen S; Larsen KO; Christensen AH; Svane IM; Zerahn B; Ellebaek E
    Acta Oncol; 2022 Jan; 61(1):45-51. PubMed ID: 34666597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
    Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
    J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
    Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
    Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
    Demarez B; Eté M; David L; Quiles N; Archier E
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
    Goodman RS; Di Guardo L; Maurichi A; Kirwin B; Khattak A; Vanella V; Lee J; Lawless A; Czapla J; Spagnoletti A; Ambrosini M; Livingstone E; Long GV; Sullivan RJ; Carlino MS; Atkinson V; Trojanello C; Ascierto PA; Schadendorf D; Warburton L; Menzies AM; Santinami M; Johnson DB
    Eur J Cancer; 2023 Nov; 194():113354. PubMed ID: 37827067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.